enGene Therapeutics Warrants
ENGNW
16 hedge funds and large institutions have $28.6M invested in enGene Therapeutics Warrants in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 10 reducing their positions, and 7 closing their positions.
358% more capital invested
Capital invested by funds: $6.26M → $28.6M (+$22.4M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
23.72% more ownership
Funds ownership: 0% → 23.72% (+24%)
33% less funds holding
Funds holding: 24 → 16 (-8)
80% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 10
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BOCH
Blue Owl Capital Holdings
New York
|
+$110K |
| 2 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$21.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIS
FCPM III Services
Naarden,
Netherlands
|
-$3.05M |
| 2 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$348K |
| 3 |
CAC
Cowen and Company
New York
|
-$316K |
| 4 |
Calamos Advisors
Naperville,
Illinois
|
-$305K |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$254K |
ENGNW Hedge Fund Activity: Q1 2024 in Review
16 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in enGene Therapeutics Warrants (ENGNW) for Q1 2024, worth a combined $28.6M — up 358% from $6.26M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ENGNW and 0 opened new positions — a net loss of 7 holders — while 10 trimmed existing stakes and 2 added.
The largest buyer was Blue Owl Capital Holdings, adding an estimated $110K. The largest seller was FCPM III Services, cutting an estimated $3.05M.
- 16 institutional investors held enGene Therapeutics Warrants (ENGNW) as of Q1 2024, down from 24 in Q4 2023.
- Funds reported $28.6M of enGene Therapeutics Warrants stock for Q1 2024, up 358% quarter-over-quarter.
- 0 funds opened new enGene Therapeutics Warrants positions in Q1 2024 and 7 closed out, a net change of -7 holders.
- The largest enGene Therapeutics Warrants buyer in Q1 2024 was Blue Owl Capital Holdings, an estimated $110K added.
- The largest enGene Therapeutics Warrants seller in Q1 2024 was FCPM III Services, an estimated $3.05M sold.
Based on aggregated 13F filings for Q1 2024.